Model Medicines
US-based, artificial intelligence-driven drug discovery and development company
Based in CA
🤖
AI Overview
With $0 in lobbying spend across 10 quarterly filings, Model Medicines is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2023 to 2025.
$0
Total Spend
3
Years Active
1
Firms Hired
2
Lobbyists Deployed
3
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $0 |
| 2024 | $0 |
| 2025 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: MED, Health Issues, Pharmacy
- •Supporting Model Medicines as it seeks federal funding to further develop, receive FDA approvals for, and begin manufacturing for their drug, MDL-001, which has been identified as a potential best-in-
- •Introduce Model Medicines and how the company is innovating at the intersection of data science, biology and drug development.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.